Core Viewpoint - The company, He Bo Pharmaceutical-B (02142), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Summary by Category Company Actions - The company plans to repurchase 200,000 shares at a total cost of HKD 2.7011 million [1] - The buyback price per share ranges from HKD 13.24 to HKD 13.67 [1] Financial Implications - The total expenditure for the share buyback reflects the company's strategy to enhance shareholder value [1]

Core Viewpoint - The company, Heptagon Pharmaceuticals-B (02142), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Summary by Categories Share Buyback Details - The company will repurchase 200,000 shares at a total cost of HKD 2.7011 million [1] - The buyback price per share ranges from HKD 13.24 to HKD 13.67 [1]

Core Viewpoint - Heptagon Pharmaceuticals-B (02142.HK) announced a share buyback of 200,000 shares at a cost of HKD 2.7 million on November 13 [1] Group 1 - The company executed a buyback program, indicating a commitment to returning value to shareholders [1] - The total expenditure for the buyback was HKD 2.7 million, reflecting the company's financial strategy [1] - The number of shares repurchased was 200,000, which may influence the stock's market performance [1]

公司名稱： 和鉑醫藥控股有限公司 呈交日期： 2025年11月13日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02142 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | ...

Group 1: Core Insights - The 8th China International Import Expo (CIIE) held from November 5 to 10 in Shanghai showcased 290 Fortune 500 and industry-leading companies, marking record highs in exhibition area and total number of exhibitors, reflecting the vitality of China's vast market [1] - The medical device and pharmaceutical health exhibition area highlighted innovative "black technology" products from multinational pharmaceutical companies, indicating a rapid transformation in the global health industry [1] - Compared to previous expos, this year's event revealed two intertwined industry trends: multinational pharmaceutical companies are withdrawing from older, less profitable drugs to focus on innovative drug development and technology collaboration, while geopolitical and supply chain risks are driving a consensus for localized operations in China [1] Group 2: R&D and Innovation - The National Medical Products Administration announced the cancellation of 80 drug registration certificates, primarily from foreign or joint-venture companies, indicating a trend of "active contraction" among foreign pharmaceutical firms in response to normalized centralized procurement and competitive restructuring [2] - Multinational pharmaceutical companies are increasing R&D investments in innovative drugs for the Chinese market, with companies like Boehringer Ingelheim committing over 5 billion yuan in the next five years [2] - Collaboration between foreign pharmaceutical companies and local biotech firms is deepening, exemplified by AstraZeneca's strategic partnership with Heptares Therapeutics, which includes a diverse cooperation model of R&D collaboration, equity investment, and establishing an innovation center in Beijing [2] Group 3: Local Production and Global Supply Chain - "Localization" emerged as a key theme for multinational pharmaceutical companies at the CIIE, driven by the need to mitigate geopolitical risks and recognize China's manufacturing and innovation capabilities [5] - A report indicated that over 60% of companies are enhancing supply security through increased regional/local procurement or advancing local production, particularly in markets emphasizing self-sufficiency [6] - Medical device company Varian announced plans for full localization of its product line by 2025, with 60% of its products exported to over 120 countries, highlighting China's role as a crucial production hub in its global supply chain [6][7] Group 4: Future Trends in Biotech - Domestic biotech companies are transitioning from "technology introduction" to "technology output," with a growing focus on innovative therapies and business development opportunities [3] - The Chinese biopharmaceutical sector is experiencing a leap from following to leading in innovation, with expectations for future business development to expand into new therapeutic areas [3] - Regulatory support from Chinese authorities is facilitating the development of innovative therapies, particularly in high-demand areas such as gastrointestinal tumors and cell gene therapy [4]

Group 1: Event Overview - The 8th China International Import Expo (CIIE) is held in Shanghai from November 5 to 10, featuring 290 Fortune 500 and industry-leading companies, marking record highs in exhibition area and total number of exhibitors, showcasing the vitality of China's large-scale market [1] - The medical devices and healthcare exhibition area serves as a key window to observe global medical trends, with multinational pharmaceutical companies presenting innovative "black technology products," including AI-enabled drug development and next-generation precision radiotherapy platforms [1] Group 2: Industry Trends - Compared to previous expos, this year's event highlights two intertwined industry trends: multinational pharmaceutical companies are withdrawing from long-listed, declining profit margin "old original research drugs" to focus resources on innovative drug development and cutting-edge technology collaboration [1] - Geopolitical factors and supply chain risks are prompting a consensus on localizing operations in China, with more multinational companies establishing R&D centers and production bases in China to create global supply chain hubs [1] Group 3: R&D and Innovation - The National Medical Products Administration announced the cancellation of 80 drug registration certificates, including products from foreign and joint-venture companies, indicating a trend of "active contraction" among foreign pharmaceutical companies in response to normalized centralized procurement and competitive restructuring [2] - Multinational pharmaceutical companies are increasing R&D investments in innovative drugs for the Chinese market, with companies like Boehringer Ingelheim planning to invest over 5 billion yuan in R&D in China over the next five years [2] - Domestic biotech companies are shifting from "technology introduction" to "technology output," with a growing focus on innovative therapies, including ADCs and PD-1, and China becoming a leading country in CAR-T technology projects [3] Group 4: Localization and Supply Chain - Localization has become a key term for multinational pharmaceutical companies, driven by the need to mitigate geopolitical risks and recognize China's manufacturing and innovation capabilities [5] - A report indicates that over 60% of companies are enhancing supply security through increased regional/local procurement or advancing local production, particularly in markets emphasizing self-sufficiency [6] - Medical device company Varian announced plans for full localization of its product line by 2025, with 60% of its products exported to over 120 countries and regions [6][7] - Cytiva has achieved 25% of its revenue from local manufacturing in China, with plans to increase this to 50% in the next 3 to 5 years [8]

Group 1 - The stock of Heptagon Pharmaceuticals-B (02142.HK) has increased by over 5%, currently up 5.46% at HKD 13.94 [1] - The trading volume reached HKD 17.1969 million [1]

Core Viewpoint - The stock of Heptagon Pharmaceuticals (02142) rose over 5%, currently up 5.46% at HKD 13.94, with a trading volume of HKD 17.1969 million, following the announcement of a strategic partnership with Evinova at the 8th China International Import Expo [1] Group 1: Strategic Partnership - Heptagon Pharmaceuticals and Evinova announced a strategic cooperation to leverage AI and digital technologies to enhance the efficiency of innovative biotherapy development [1] - The partnership aims to build an AI-driven open ecosystem for drug research and development by utilizing each company's strengths [1] Group 2: AI Platform Development - Heptagon Pharmaceuticals launched its first fully human AIHCAb model driven by the Hu-mAtrIx™ AI platform during a global R&D day event in Shanghai [1] - The model is based on proprietary HarbourMice® platform data and integrates a fine-tuned large language model (LLM) for sequence generation, complemented by high-precision AI classification and drugability prediction models [1] - Unlike traditional screening methods, the platform achieves a closed-loop process of AI design, intelligent screening, and wet lab validation [1]

Core Viewpoint - The stock of Heptagon Pharmaceuticals (02142) rose over 5%, currently up 5.46% at HKD 13.94, with a trading volume of HKD 17.1969 million, following the announcement of a strategic partnership with Evinova at the 8th China International Import Expo to enhance the efficiency of innovative biotherapy development through AI and digital technologies [1] Group 1 - Heptagon Pharmaceuticals and Evinova will leverage their respective strengths to build an AI-driven open ecosystem for drug development [1] - The company recently launched its first fully human AIHCAb model driven by the Hu-mAtrIx AI platform during a global R&D day event in Shanghai [1] - The AIHCAb model is based on proprietary HarbourMice platform data and integrates a fine-tuned large language model (LLM) for sequence generation, complemented by high-precision AI classification and drugability prediction models [1] Group 2 - The platform differs from traditional screening methods by achieving a closed-loop process of AI design, intelligent screening, and wet lab validation [1]

Group 1 - The company, HAPO Pharmaceutical-B (02142), announced a share buyback plan [1] - The company will spend HKD 1.978 million to repurchase 150,000 shares [1]